Cargando…

289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification

OBJECTIVES/GOALS: This study explored whether gabapentin (GBN) differentially impacted heart rate variability (HRV) and whether HRV was associated with opioid withdrawal ratings among participants with opioid use disorder (OUD) undergoing a randomized, double blind placebo-controlled, trial (RCT) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Lauren, Weaver, Jackson, Mancino, Michael, Addicott, Merideth, Larson-Prior, Linda, Oliveto, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129735/
http://dx.doi.org/10.1017/cts.2023.345
_version_ 1785030816173129728
author Russell, Lauren
Weaver, Jackson
Mancino, Michael
Addicott, Merideth
Larson-Prior, Linda
Oliveto, Alison
author_facet Russell, Lauren
Weaver, Jackson
Mancino, Michael
Addicott, Merideth
Larson-Prior, Linda
Oliveto, Alison
author_sort Russell, Lauren
collection PubMed
description OBJECTIVES/GOALS: This study explored whether gabapentin (GBN) differentially impacted heart rate variability (HRV) and whether HRV was associated with opioid withdrawal ratings among participants with opioid use disorder (OUD) undergoing a randomized, double blind placebo-controlled, trial (RCT) of GBN during a buprenorphine (BUP)-assisted taper. METHODS/STUDY POPULATION: Participants (ages 18-64) with OUD, no recent use of benzodiazepines/barbiturates, and no major psychiatric disorders or unstable medical conditions were enrolled in the RCT, inducted onto BUP starting week 1 day 1 and randomly assigned to receive adjunct GBN or placebo starting week 1 day 3. All participants began a 10-day BUP-taper beginning week 2 day 3. HRV measures were assessed on week 1 day 2 (before GBN/placebo induction), week 2 day 2, and week 3 day 5 (end of BUP taper). HRV metrics were analyzed using Two Sample T-Test to determine differences between GBN vs. Placebo. Correlations between HRV metrics and opioid withdrawal ratings administered at the above timepoints will be analyzed using Spearman correlation. RESULTS/ANTICIPATED RESULTS: 28 participants underwent at least 1 HRV session that resulted in usable data. Preliminary statistical analyses revealed that HRV trended lower for GBN subjects during PB exercises than Placebo subjects, demonstrated by a higher mean heart rate for GBN subjects compared to Placebo subjects (p=0.0506) at the end of the BUP-taper (week 3 day 5). We expect future analyses to demonstrate a negative correlation between certain HRV metrics indicative of parasympathetic tone and opioid withdrawal rating assessment scores indicative of withdrawal severity. Such findings would demonstrate an association between opioid withdrawal severity and lower parasympathetic tone and HRV. DISCUSSION/SIGNIFICANCE: Individuals with OUD have previously been shown to have a lower parasympathetic tone than individuals without OUD. Additionally, opioid withdrawal has been shown to be associated with reduced parasympathetic tone. Our initial findings suggest that adjunct GBN administration was not associated with lower parasympathetic tone during PB exercises.
format Online
Article
Text
id pubmed-10129735
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-101297352023-04-26 289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification Russell, Lauren Weaver, Jackson Mancino, Michael Addicott, Merideth Larson-Prior, Linda Oliveto, Alison J Clin Transl Sci Precision Medicine/Health OBJECTIVES/GOALS: This study explored whether gabapentin (GBN) differentially impacted heart rate variability (HRV) and whether HRV was associated with opioid withdrawal ratings among participants with opioid use disorder (OUD) undergoing a randomized, double blind placebo-controlled, trial (RCT) of GBN during a buprenorphine (BUP)-assisted taper. METHODS/STUDY POPULATION: Participants (ages 18-64) with OUD, no recent use of benzodiazepines/barbiturates, and no major psychiatric disorders or unstable medical conditions were enrolled in the RCT, inducted onto BUP starting week 1 day 1 and randomly assigned to receive adjunct GBN or placebo starting week 1 day 3. All participants began a 10-day BUP-taper beginning week 2 day 3. HRV measures were assessed on week 1 day 2 (before GBN/placebo induction), week 2 day 2, and week 3 day 5 (end of BUP taper). HRV metrics were analyzed using Two Sample T-Test to determine differences between GBN vs. Placebo. Correlations between HRV metrics and opioid withdrawal ratings administered at the above timepoints will be analyzed using Spearman correlation. RESULTS/ANTICIPATED RESULTS: 28 participants underwent at least 1 HRV session that resulted in usable data. Preliminary statistical analyses revealed that HRV trended lower for GBN subjects during PB exercises than Placebo subjects, demonstrated by a higher mean heart rate for GBN subjects compared to Placebo subjects (p=0.0506) at the end of the BUP-taper (week 3 day 5). We expect future analyses to demonstrate a negative correlation between certain HRV metrics indicative of parasympathetic tone and opioid withdrawal rating assessment scores indicative of withdrawal severity. Such findings would demonstrate an association between opioid withdrawal severity and lower parasympathetic tone and HRV. DISCUSSION/SIGNIFICANCE: Individuals with OUD have previously been shown to have a lower parasympathetic tone than individuals without OUD. Additionally, opioid withdrawal has been shown to be associated with reduced parasympathetic tone. Our initial findings suggest that adjunct GBN administration was not associated with lower parasympathetic tone during PB exercises. Cambridge University Press 2023-04-24 /pmc/articles/PMC10129735/ http://dx.doi.org/10.1017/cts.2023.345 Text en © The Association for Clinical and Translational Science 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Precision Medicine/Health
Russell, Lauren
Weaver, Jackson
Mancino, Michael
Addicott, Merideth
Larson-Prior, Linda
Oliveto, Alison
289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification
title 289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification
title_full 289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification
title_fullStr 289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification
title_full_unstemmed 289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification
title_short 289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification
title_sort 289 heart rate variability in opioid use disordered participants undergoing buprenorphine-assisted detoxification
topic Precision Medicine/Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129735/
http://dx.doi.org/10.1017/cts.2023.345
work_keys_str_mv AT russelllauren 289heartratevariabilityinopioidusedisorderedparticipantsundergoingbuprenorphineassisteddetoxification
AT weaverjackson 289heartratevariabilityinopioidusedisorderedparticipantsundergoingbuprenorphineassisteddetoxification
AT mancinomichael 289heartratevariabilityinopioidusedisorderedparticipantsundergoingbuprenorphineassisteddetoxification
AT addicottmerideth 289heartratevariabilityinopioidusedisorderedparticipantsundergoingbuprenorphineassisteddetoxification
AT larsonpriorlinda 289heartratevariabilityinopioidusedisorderedparticipantsundergoingbuprenorphineassisteddetoxification
AT olivetoalison 289heartratevariabilityinopioidusedisorderedparticipantsundergoingbuprenorphineassisteddetoxification